Synthetic Biology

Stanford researchers used generative AI (Evo 2) to design and synthesize novel bacteriophages. The AI generated nearly 300 potential phage genomes, with 16 showing potent activity against E. coli. This approach, utilizing computational screening and a cocktail strategy, enhances therapeutic potential and offers a new weapon against antibiotic resistance. The Evo 2 model is now open-source to accelerate synthetic biology innovation.

eXoZymes (NASDAQ:EXOZ) unveils AI-programmed exozymes, cell-free enzyme systems enabling scalable, sustainable chemical synthesis beyond cellular constraints. First commercial entity NCTx targets NAFLD—affecting 25% globally—via streamlined production eliminating downstream metabolomics. Backed by DoD/DOE grants, the platform advances biofuels and therapeutics with modular integration, avoiding fermentation inefficiencies. Framed as a SaaS model for enzyme licensing, it challenges legacy competitors while investors monitor NAFLD proof-of-concept data and partner deal terms.